Suppr超能文献

主动监测所有缺乏干预临床标准的小肾肿瘤的风险分层。

Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention.

机构信息

Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Department of Urology, Cairo University, Cairo, Egypt.

出版信息

J Urol. 2021 Aug;206(2):229-239. doi: 10.1097/JU.0000000000001714. Epub 2021 Mar 29.

Abstract

PURPOSE

Despite general indolence of small renal masses and no known adversity from treatment delays, broad usage of active surveillance as a means to risk-stratify patients with small renal masses for more selective treatment has not been studied. We describe outcomes for a novel approach in which active surveillance was recommended to all patients with small renal masses lacking predefined progression criteria for intervention.

MATERIALS AND METHODS

All nondialysis dependent patients with nonmetastatic small renal masses seen by 1 urologist at a comprehensive cancer center during January 2013-September 2017 were managed with active surveillance if standardized progression criteria for intervention were absent, with delayed intervention recommended only upon progression criteria for intervention development. Progression criteria for intervention were defined prospectively as small renal mass-related symptoms, unfavorable histology, cT3a stage or either of the following without benign neoplastic biopsy histology: longest tumor diameter >4 cm; growth rate >5 mm/year for longest tumor diameter ≤3 cm or >3 mm/year for longest tumor diameter >3 cm.

RESULTS

In all, 96% (123/128) of patients with small renal masses lacked progression criteria for intervention at presentation and underwent active surveillance. With median/mean 31/34 months followup, none developed metastasis and 30% (37/123) developed progression criteria for intervention, 78% (29/37) of whom underwent delayed intervention. One (1%) patient crossed over to delayed intervention without progression criteria for intervention. Three-year progression criteria for intervention-free and delayed intervention-free rates were 72% and 75%, respectively. Delayed intervention resections were enriched (62%) for pT3 and/or nuclear grade 3-4 malignant pathology, with no benign resections.

CONCLUSIONS

Active surveillance using predefined progression criteria for intervention in otherwise unselected patients with small renal masses allows intervention to be focused on at-risk small renal masses with common adverse pathology, avoiding treatment for most patients with small renal masses. Long-term delayed intervention and oncologic safety require study.

摘要

目的

尽管小肾肿瘤通常惰性且治疗延迟不会带来已知的不良后果,但广泛应用主动监测作为一种风险分层方法,对小肾肿瘤患者进行更有选择性的治疗,尚未得到研究。我们描述了一种新方法的结果,该方法建议所有缺乏干预性进展标准的小肾肿瘤患者进行主动监测,如果不存在标准化的干预进展标准,则建议仅在出现干预进展标准时延迟干预。干预进展标准前瞻性地定义为小肾肿瘤相关症状、不良组织学、cT3a 期或以下任何一种情况而无良性肿瘤活检组织学:最长肿瘤直径>4cm;最长肿瘤直径≤3cm 时生长速度>5mm/年,最长肿瘤直径>3cm 时生长速度>3mm/年。

材料与方法

2013 年 1 月至 2017 年 9 月期间,在一家综合癌症中心由 1 位泌尿科医生诊治的所有非透析依赖的非转移性小肾肿瘤患者,如果缺乏干预性进展标准,则采用主动监测,如果不存在标准化的干预进展标准,则建议仅在出现干预进展标准时延迟干预。干预进展标准前瞻性地定义为小肾肿瘤相关症状、不良组织学、cT3a 期或以下任何一种情况而无良性肿瘤活检组织学:最长肿瘤直径>4cm;最长肿瘤直径≤3cm 时生长速度>5mm/年,最长肿瘤直径>3cm 时生长速度>3mm/年。

结果

共有 128 例小肾肿瘤患者的 96%(123/128)在就诊时缺乏干预性进展标准,接受了主动监测。中位/平均随访 31/34 个月,无患者发生转移,30%(37/123)出现干预进展标准,其中 78%(29/37)接受了延迟干预。1 例(1%)患者在没有干预进展标准的情况下接受了延迟干预。3 年的干预无进展和延迟干预无进展率分别为 72%和 75%。延迟干预切除标本中富含 pT3 和/或核分级 3-4 级恶性病理,无良性切除标本。

结论

在未选择的小肾肿瘤患者中,使用预设的干预进展标准进行主动监测可以将干预重点集中在具有常见不良病理的高危小肾肿瘤上,避免对大多数小肾肿瘤患者进行治疗。长期延迟干预和肿瘤安全性需要进一步研究。

相似文献

1
Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention.
J Urol. 2021 Aug;206(2):229-239. doi: 10.1097/JU.0000000000001714. Epub 2021 Mar 29.
2
Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance.
J Urol. 2014 Sep;192(3):659-64. doi: 10.1016/j.juro.2014.03.038. Epub 2014 Mar 15.
3
Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry.
J Urol. 2018 Mar;199(3):641-648. doi: 10.1016/j.juro.2017.09.087. Epub 2017 Sep 23.
4
Extended Duration of Active Surveillance of Small Renal Masses: A Prospective Cohort Study.
J Urol. 2019 Jul;202(1):57-61. doi: 10.1097/JU.0000000000000075. Epub 2019 Jun 7.
5
Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes.
Eur Urol. 2018 Aug;74(2):157-164. doi: 10.1016/j.eururo.2018.03.011. Epub 2018 Apr 4.
8
Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance.
Eur Urol. 2011 May;59(5):863-7. doi: 10.1016/j.eururo.2011.02.023. Epub 2011 Feb 22.

引用本文的文献

1
Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative.
Eur Urol Open Sci. 2025 Mar 26;75:11-19. doi: 10.1016/j.euros.2025.02.005. eCollection 2025 May.
4
Avoidable Benign Kidney Tumor Resections-Data from a Tertiary Care Cancer Institute.
J Kidney Cancer VHL. 2024 Oct 1;11(4):1-9. doi: 10.15586/jkcvhl.v11i4.286. eCollection 2024.
5
Accuracy, safety, and diagnostic prediction of percutaneous renal mass biopsy and subsequent changes in treatment.
Wideochir Inne Tech Maloinwazyjne. 2024 Mar;19(1):113-121. doi: 10.5114/wiitm.2024.135411. Epub 2024 Feb 14.
7
The evolving management of small renal masses.
Nat Rev Urol. 2024 Jul;21(7):406-421. doi: 10.1038/s41585-023-00848-6. Epub 2024 Feb 16.
8
Stability of renal parenchymal volume and function during active surveillance of renal oncocytoma patients.
Urol Oncol. 2023 Apr;41(4):208.e15-208.e23. doi: 10.1016/j.urolonc.2023.01.006. Epub 2023 Feb 25.
9
Urine Molecular Biomarkers for Detection and Follow-Up of Small Renal Masses.
Int J Mol Sci. 2022 Dec 17;23(24):16110. doi: 10.3390/ijms232416110.

本文引用的文献

2
Identification of tumor size as the only factor associated with nondiagnostic biopsies in patients with small renal masses.
Can Urol Assoc J. 2020 May;14(5):E220-E223. doi: 10.5489/cuaj.6103. Epub 2019 Nov 29.
3
Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States.
Eur Urol Oncol. 2019 Jul;2(4):343-348. doi: 10.1016/j.euo.2018.08.023. Epub 2018 Sep 25.
4
Extended Duration of Active Surveillance of Small Renal Masses: A Prospective Cohort Study.
J Urol. 2019 Jul;202(1):57-61. doi: 10.1097/JU.0000000000000075. Epub 2019 Jun 7.
5
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
Eur Urol. 2019 May;75(5):799-810. doi: 10.1016/j.eururo.2019.02.011. Epub 2019 Feb 23.
6
Use of delayed intervention for small renal masses initially managed with active surveillance.
Urol Oncol. 2019 Jan;37(1):18-25. doi: 10.1016/j.urolonc.2018.10.001. Epub 2018 Nov 13.
7
Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma.
Eur Urol. 2018 Dec;74(6):825-832. doi: 10.1016/j.eururo.2018.08.028. Epub 2018 Sep 24.
8
Determinants of Active Surveillance in Patients With Small Renal Masses.
Urology. 2019 Jan;123:167-173. doi: 10.1016/j.urology.2018.07.021. Epub 2018 Jul 27.
9
The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass.
J Urol. 2018 Nov;200(5):981-988. doi: 10.1016/j.juro.2018.05.081. Epub 2018 May 22.
10
Is Routine Renal Tumor Biopsy Associated with Lower Rates of Benign Histology following Nephrectomy for Small Renal Masses?
J Urol. 2018 Oct;200(4):731-736. doi: 10.1016/j.juro.2018.04.015. Epub 2018 Apr 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验